| Malignant neoplasm of breast

Kisqali vs Herceptin

Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.

Deep comparison between: Kisqali vs Herceptin with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHerceptin has a higher rate of injection site reactions vs Kisqali based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Herceptin but not Kisqali, including UnitedHealthcare

Category

Kisqali

Herceptin

At A Glance

RouteOral

FrequencyOnce daily (21/28-day cycle)

ClassCDK4/6 inhibitor

RouteIV infusion

FrequencyWeekly or every 3 weeks

ClassHER2 antagonist

Indications

Malignant neoplasm of breast
Advanced breast cancer

Malignant neoplasm of breast
Gastric Adenocarcinoma
Adenocarcinoma of the gastroesophageal junction

Dosing

Malignant neoplasm of breast 400 mg (two 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with an aromatase inhibitor, for 3 years or until disease recurrence or unacceptable toxicity.

Advanced breast cancer 600 mg (three 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with fulvestrant or an aromatase inhibitor.

Malignant neoplasm of breast (adjuvant) Schedule 1: 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly over 30 min for 12 or 18 weeks, then 6 mg/kg every 3 weeks to complete 52 weeks; Schedule 2: 8 mg/kg loading dose over 90 min IV, then 6 mg/kg every 3 weeks for 52 weeks.

Malignant neoplasm of breast (metastatic) 4 mg/kg loading dose as 90-min IV infusion, then 2 mg/kg weekly as 30-min IV infusions until disease progression.

Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90-min IV infusion, then 6 mg/kg over 30-90 min IV every 3 weeks until disease progression, in combination with cisplatin and capecitabine or 5-fluorouracil.

Contraindications

—

Drug Interactions

1170View drug interactions

1103View drug interactions

Adverse Reactions

Most common (>=20%) Neutrophils decreased, leukocytes decreased, lymphocytes decreased, hemoglobin decreased, ALT increased, AST increased, infections, nausea, fatigue, headache, creatinine increased, platelets decreased, diarrhea, vomiting, alopecia, cough, rash, back pain

Serious Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions (SJS, TEN), QT interval prolongation, hepatotoxicity, neutropenia

Postmarketing Interstitial lung disease/pneumonitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/DRESS

Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia

Serious Cardiomyopathy, infusion reactions, embryo-fetal toxicity, pulmonary toxicity, exacerbation of chemotherapy-induced neutropenia

Postmarketing Infusion reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome

Pharmacology

Ribociclib is a CDK4/6 inhibitor that blocks cyclin D-CDK4/6-mediated phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle in the G1 phase and reducing proliferation in breast cancer models; in combination with antiestrogen therapy (letrozole or fulvestrant), it produces greater tumor growth inhibition than either agent alone.

Humanized IgG1 kappa monoclonal antibody (anti-HER2) that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Kisqali